In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Pacira BioSciences trades substantially below its PERT-weighted fair value of $113.87, indicating significant upside potential. However, low profitability and efficiency scores paired with high Monte Carlo volatility (CV 140.78%) imply elevated investment risk. A zero downside risk under scenarios below current price suggests limited near-term price depreciation.